Why Zynerba's stock soared 62% this week
Zynerba's stock price closed up 62 percent Thursday, at $9.44 per share, after the specialty pharmaceutical company posted positive study results from a midstage clinical trial of its experimental treatment for a rare developmental disorder.
The Devon company is attempting to develop synthetic cannabinoid-based therapies for a variety of disorders.
Zynerba said in a study of its ZYN002 cannabidiol gel in pediatric and adolescent patients with Fragile X syndrome that the new drug candidates met…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: John George Source Type: news
More News: American Health | Clinical Trials | Fragile X Syndrome | Health Management | Pediatrics | Study